Group 2392.png

In HR+ / HER2 - eBC:

 

Despite SoC, patients remain at risk of recurrence¹

 

Within 4 years, 1 in 6 will experience a recurrence*¹

Screenshot 2025-06-26 at 11.23.58 PM 1.png

In ER+ eBC:

Risk of metastatic recurrence remains regardless of ET or nodal status3

Group 2393.png

Risk of metastatic recurrence over time3

Recurrence continued at a steady rate through 20 years of follow-up despite 5 years of adjuvant endocrine therapy. Risk of recurrence was strongly correlated with the TN status at diagnosis. However, even low-grade T1N0 disease carried ongoing risk of recurrence.3

Group 2394.png

*In the NATALEE study 4-year iDFS was 83.6% in patients who received NSAI alone.1

†After 3 years in the NSAI alone group, 283 patients experienced a recurrence, 256 of which were distant events, defined as: Distant recurrence, death (any cause), or second primary non-breast invasive cancer, excluding basal and squamous cell carcinomas of the skin. After 4 years, 340 patients experienced
a recurrence, 311 of which were distant events.1

EBCTCG, Early Breast Cancer Trialist’s Collaborative Group; eBC, early breast cancer; ET, endocrine therapy; ER, oestrogen receptor; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; iDFS, invasive disease-free survival; NSAI, non-steroidal aromatase inhibitor; SoC, standard of care; NO, no nodal involvement; N1, 1–3 axillary lymph nodes; N2, 4–9 axillary lymph nodes; T, tumour; T1, tumor is 2 cm or less; T2, tumour is more than 2 cm but less than 5 cm.

KISQALI® NSS - UAE

PDF
View

References

  1. Fasching PA, et al. Oral LBA13. Presented at the European Society for Medical Oncology Congress 2024, 13–17 September, Barcelona, Spain.

  2. Harbeck N, et al. Nat Rev Dis Primers. 2019;5:66.

  3. Pan H, et al. N Engl J Med. 2017;377:1836–1846.